RecruitingPhase 2NCT04452500
Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)
Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD)
Sponsor
VA Office of Research and Development
Enrollment
40 participants
Start Date
Oct 15, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to test the drug CORT108297, which blocks the hormone cortisol, for treatment of PTSD in Veterans, and establish a safety profile that will inform the design of future studies.
Eligibility
Min Age: 18 YearsMax Age: 69 Years
Inclusion Criteria9
- History of US military service
- Capable of reading and understanding English
- Able to provide written informed consent
- Symptoms of PTSD (must score 23 or greater on the CAPS-5 assessment at screening visit)
- Men and pre-menopausal women must agree to use two forms of reliable contraception, one of which is a barrier method.
- Participants who use an SSRI or SNRI medication for PTSD must be on a stable dose for 8 weeks before enrollment.
- Participants who use trazodone for sleep must be on a stable dose.
- Participants who use opiate pain medication must be on a stable dose.
- For participants who are in psychotherapy, treatment must be stable for 6 weeks.
Exclusion Criteria25
- Alcohol use that meets criteria for Alcohol Use Disorder in past 3 months.
- Marijuana or other drug use that meets criteria for Substance Use Disorder in past 3 months.
- Ever diagnosed with: Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Obsessive-Compulsive Disorder, or Major Depressive Disorder with Psychotic Features
- Experienced any psychologically traumatic event in the past 3 months
- Currently using certain antidepressant medications such as doxepin or tricyclics
- Currently using certain mood stabilizers, such as lithium
- Currently using antipsychotic medication
- High risk for suicide or violent behavior
- Has sleep apnea and not using any treatment, such as CPAP
- Currently using corticosteroid medication (oral or inhaled)
- History of neurological disease
- Angina, congestive heart failure or low blood pressure
- Heart attack in the past 6 months
- Heart block or irregular heartbeat
- Kidney failure, liver failure or pancreatitis
- Severe chronic obstructive pulmonary disease (COPD)
- History of liver disease with lab results on AST or ALT more than 2 times the normal readings
- History of kidney disease with lab results on eGFR less than 60 ml/min
- History of additional risk factors for Torsades de pointes, such as heart failure, low potassium, or family history of a heart rhythm disorder called long QT syndrome
- Use of certain medications that can affect heart rhythm
- Use of certain medications that can interfere with the effects of the study drug
- High blood pressure that is not controlled by medication
- Diabetes that is not well-controlled
- History of certain types of head injuries
- Mild cognitive impairment
Interventions
DRUGCORT108297
CORT108297- 180mg daily for 7 days
DRUGPlacebo
Placebo- 180mg daily for 7 days
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04452500
Related Trials
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
NCT070107571 location
Evaluation of the Impact of Participation in a Psycho-education Program for Victims of Sexual Violence
NCT067183871 location
Behavioral Health Collaborative Care Model in Post-ICU Clinic Family Pilot
NCT073907861 location
Behavioral Health Collaborative Care Model in an ICU Recovery Clinic
NCT073725861 location
Open-Label Psilocybin Study in Transdiagnostic Population
NCT064424231 location